Stocktoria
REGENERON PHARMACEUTICALS, INC. REGN
REGENERON PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $6.6B | $5.1B | $5.9B | $4.9B |
| R&D expense | $5.9B | $5.1B | $4.4B | $3.6B | $2.9B | $2.6B | $2.5B | $1.5B | $2.1B | $2.1B |
| SG&A expense | $2.7B | $3.0B | $2.6B | $2.1B | $1.8B | $1.3B | $1.3B | $1.1B | $1.3B | $1.2B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B |
| Interest expense | — | — | $73.0M | $59.4M | $57.3M | $56.9M | $30.2M | $28.2M | $25.1M | $7.2M |
| Income tax | $725.8M | $367.3M | $245.7M | $520.4M | $1.3B | $297.2M | $313.3M | $109.1M | $880.0M | $434.3M |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $895.5M |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B | $2.6B | $2.4B | $2.2B | $1.3B | $1.5B |
| Cash & equivalents | $3.1B | $2.5B | $2.7B | $3.1B | $2.9B | $2.2B | $1.6B | $1.5B | $812.7M | $535.2M |
| Inventory | $3.2B | $3.1B | $2.6B | $2.4B | $2.0B | $1.9B | $1.4B | $1.2B | $726.1M | $399.4M |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B | $17.2B | $14.8B | $11.7B | $8.8B | $7.0B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B | $6.1B | $3.7B | $3.0B | $2.6B | $2.5B |
| Shareholders' equity | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B | $11.0B | $11.1B | $8.8B | $6.1B | $4.4B |
Growth · year-over-year · Revenue CAGR 12.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +1.0% | +8.3% | +7.8% | -24.3% | +89.1% | +29.6% | +27.4% | -12.4% | +20.8% | +18.4% |
| Net income growth | +2.1% | +11.6% | -8.9% | -46.3% | +129.9% | +66.0% | -13.4% | +104.0% | +33.8% | +40.8% |
| EPS growth | +8.2% | +10.3% | -9.0% | -46.9% | +135.8% | +65.3% | -13.3% | +105.9% | +34.3% | +39.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.